参考文献/References:
[1]Denton CP,Khanna D.Systemic sclerosis[J].The Lancet,2017,390(10103):1685-1699. [2]Khanna D,Tashkin DP,Denton CP,et al.Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease[J].Rheumatology,2018. [3]Adler S,Huscher D,Siegert E,et al.Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group[J].Arthritis research & therapy,2018,20(1):17. [4]Tashkin DP,Elashoff R,Clements PJ,et al.Cyclophosphamide versus placebo in scleroderma lung disease[J].The New England journal of medicine.2006,354(25):2655-2666. [5]Tashkin DP,Roth MD,Clements PJ,et al.Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II):a randomised controlled,double-blind, parallel group trial[J].The Lancet Respiratory medicine,2016,4(9):708-719. [6]Koutroumpas A,Ziogas A,Alexiou I,et al.Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease[J].Clinical rheumatology,2010,29(10):1167-1168. [7]Gerbino AJ,Goss CH,Molitor JA.Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease[J].Chest,2008,133(2):455-460. [8]Vanthuyne M,Blockmans D,Westhovens R,et al.A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis[J].Clin Exp Rheumatol,2007,25(2):287-292. [9]Panopoulos ST,Bournia VK,Trakada G,et al.Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: A 2-year case control study[J].Lung,2013,191(5):483-489. [10]Shenoy PD,Bavaliya M,Sashidharan S,et al.Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy:A single-centre, retrospective analysis[J].Arthritis Research and Therapy,2016,18(1):123. [11]Poormoghim H,Rezaei N,Sheidaie Z,et al.Systemic sclerosis:comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective tients with systemic sclerosis-associated interstitial lung disease (SENSCIS)[J].Clin Exp Rheumatol,2017,35 Suppl 10(4):75-81. [19]Miura Y,Saito T,Fujita K,et al.Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease[J].Sarcoidosis vasculitis＆diffuse lung diseases official journal of Wasog,2014,31(3):235-238. [20]Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial[J]. The Journal of rheumatology,2016,43(9):1672-1679. [21]Del PapaN, Onida F,Zaccara E,et al.Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis[J].Bone Marrow Transplantation,2016,52(1):53-58. [22]Van Laar JM,Naraghi K,Tyndall A.Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis[J]. Rheumatology,2015,54(12):2126-2133. [23]Kowal-Bielecka O,Fransen J,Avouac J,et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Annals of the rheumatic diseases,2017,76(8):1327-1329. [24]Miele CH,Schwab K,Saggar R,et al.Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience[J].Annals of the American Thoracic Society,2016,13(6):793-802.study[J].Rheumatology international,2014,34(12):1691-1699. [12]Nadashkevich O,Davis P,Fritzler M,et al.A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis[J].Clinical Rheumatology,2006,25 (2):205-212. [13]Lepri G,Avouac J,Airo P,et al.Effects of rituximab in connective tissue disorders related interstitial lung disease[J].Clinical and experimental rheumatology,2016,34 Suppl 100(5):181-185. [14]Daoussis D,Liossis SN,Tsamandas AC,et al.Experience with rituximab in scleroderma:results from a 1-year,proof-of-principle study[J].Rheumatology,2010,49(2):271-280. [15]Saunders P,Tsipouri V,Keir GJ,et al.Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL):study protocol for a randomised controlled trial[J].Trials,2017,18(1):275. [16]De Lauretis A,Sestini P,Pantelidis P,et al.Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis[J].The Journal of rheumatology,2013,40(4):435-446. [17]Khanna D,Denton CP,Jahreis A,et al.Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate):a phase 2,randomized,controlled trial[J].Lancet,2016,387(10038):2630-2640. [18]Distler O,Brown KK,Distler JHW,et al.Design of a randomised, placebo-controlled clinical trial of nintedanib in pa
相似文献/References:
[1]孙 杰,李 洋.系统性硬化症纤维化治疗新靶点研究[J].医学信息,2018,31(09):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
SUN Jie,LI Yang.A New Target for the Treatment of Systemic Sclerosis with Fibrosis[J].Medical Information,2018,31(19):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
[2]肖应梅,江 涛.ANCA相关性血管炎肺受累研究现状[J].医学信息,2020,33(05):33.[doi:10.3969/j.issn.1006-1959.2020.05.011]
XIAO Ying-mei,JIANG Tao.Research Status of ANCA-related Vasculitis Pulmonary Involvement[J].Medical Information,2020,33(19):33.[doi:10.3969/j.issn.1006-1959.2020.05.011]
[3]刘孟国,傅雯雯.警报素在系统性硬化症发病机制中的作用[J].医学信息,2021,34(04):40.[doi:10.3969/j.issn.1006-1959.2021.04.011]
LIU Meng-guo,FU Wen-wen.The Role of Alarmins in the Pathogenesis of Systemic Sclerosis[J].Medical Information,2021,34(19):40.[doi:10.3969/j.issn.1006-1959.2021.04.011]
[4]刘翠莲,谢静仪,胡 秋,等.肌炎特异性抗体与特发性炎性肌病患者症状特征及短期预后的相关性分析[J].医学信息,2022,35(02):83.[doi:10.3969/j.issn.1006-1959.2022.02.020]
LIU Cui-lian,XIE Jing-yi,HU Qiu,et al.Correlation Analysis of Myositis Specific Antibody with Symptom Characteristicsand Short-term Prognosis in Patients with Idiopathic Inflammatory Myopathy[J].Medical Information,2022,35(19):83.[doi:10.3969/j.issn.1006-1959.2022.02.020]
[5]陈 英,周淑红,王 妍,等.硬皮病相关间质性肺病与特发性肺纤维化的临床比较[J].医学信息,2023,36(10):53.[doi:10.3969/j.issn.1006-1959.2023.10.013]
CHEN Ying,ZHOU Shu-hong,WANG Yan,et al.Clinical Comparison Between Scleroderma Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis[J].Medical Information,2023,36(19):53.[doi:10.3969/j.issn.1006-1959.2023.10.013]
[6]程丽丽,黄传兵,汤忠富,等.从肺论治系统性硬化症合并间质性肺病的经验举隅[J].医学信息,2022,35(10):155.[doi:10.3969/j.issn.1006-1959.2022.10.039]